Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Wall Street ends 2026 positively with tech stocks dominating, but concerns over valuations drive interest in smaller AI ...

A dad in Virginia ended up turning to social media for help after becoming confused by a first-grade math problem. Math seems to be a problem for many young Americans. In 2022, the Programme for ...

Undergraduate students across North America sat down on Saturday to write a grueling six-hour math exam, many of them unlikely to solve a single problem. The notoriously brutal William Lowell Putnam ...